8-KLeadership Changes

REGENERON PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Jan 18, 2018)

Filed January 18, 2018For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) announced a change in its Board of Directors. Charles A. Baker, a long-serving board member, has decided not to seek re-election at the upcoming 2018 annual shareholders meeting, which is expected on June 8, 2018. Mr. Baker, who is 85 years old, will retire after a remarkable 29 years of service to the company. This departure is not indicative of any disagreements between Mr. Baker and Regeneron regarding the company's operations, policies, or practices. Investors can view this as a planned succession and an orderly transition, given Mr. Baker's extensive tenure and age. The company will provide updates on board composition as relevant.

Key Highlights

  • 1Charles A. Baker, a board director, will retire from the board effective June 8, 2018.
  • 2Mr. Baker will not stand for re-election at the 2018 annual shareholders meeting.
  • 3His decision to retire is not due to any disagreement with Regeneron.
  • 4Mr. Baker has served on the Board for 29 years.
  • 5He was one of the company's earliest non-employee directors.
  • 6This filing is an 8-K Current Report concerning a departure of a director.

Frequently Asked Questions

Charles A. Baker is a member of the Board of Directors at Regeneron Pharmaceuticals, Inc. He has been a director for 29 years and is one of the company's earliest non-employee directors.

Mr. Baker has decided not to stand for re-election when his current term expires. He will retire from his position as a member of the Board effective as of the conclusion of the 2018 annual shareholders meeting. His decision is not due to any disagreement with the company.

Mr. Baker's retirement from the Board will be effective as of the conclusion of the 2018 annual shareholders meeting, which is expected to be held on June 8, 2018.

No, the filing explicitly states that Mr. Baker's decision not to stand for re-election was not due to any disagreement with the Company on any matter relating to Regeneron’s operations, policies or practices. This appears to be a planned retirement after a long tenure.